Moore Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Moore Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40,000	Closed	-$4.98M	–	670
2024 Q4	$3.34M	Buy	+40,000	New	+$3.29M	0.04%	279
2024 Q3	–	Sell	-25,000	Closed	-$1.71M	–	582
2024 Q2	$1.71M	Hold	25,000	–	–	0.03%	282
2024 Q1	$1.73M	Hold	25,000	–	–	0.03%	273
2023 Q4	$1.79M	Buy	+25,000	New	+$1.44M	0.03%	231
2022 Q4	–	Sell	-180,185	Closed	-$8.38M	–	657
2022 Q3	$8.38M	Sell	180,185 -6,121	-3%	-$320K	0.2%	95
2022 Q2	$10.6M	Buy	186,306 +107,638	+137%	+$6.1M	0.28%	69
2022 Q1	$4.81M	Sell	78,668 -1,632	-2%	-$84.8K	0.12%	213
2021 Q4	$4.2M	Buy	+80,300	New	+$3.37M	0.08%	258
2016 Q1	–	Sell	-45,000	Closed	-$2.42M	–	354
2015 Q4	$2.42M	Buy	+45,000	New	+$2.27M	0.08%	192

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Moore Capital Management's ITCI Position: Q1 2025 in Review

Moore Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 40,000 shares — an estimated $4.98M sold.

Moore Capital Management first reported a position in ITCI in Q4 2015 and held it in 9 quarters. The position peaked at $10.6M in Q2 2022. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Moore Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Moore Capital Management sold 40,000 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $4.98M.
Moore Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 9 quarters.
Moore Capital Management's Intra-Cellular Therapies Inc. position peaked at $10.6M in Q2 2022.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Moore Capital Management's 13F filing for Q1 2025, filed 15 May 2025.